CN102357082A - 一种埃索美拉唑钠的冻干粉针剂及其制备方法 - Google Patents
一种埃索美拉唑钠的冻干粉针剂及其制备方法 Download PDFInfo
- Publication number
- CN102357082A CN102357082A CN2011103375373A CN201110337537A CN102357082A CN 102357082 A CN102357082 A CN 102357082A CN 2011103375373 A CN2011103375373 A CN 2011103375373A CN 201110337537 A CN201110337537 A CN 201110337537A CN 102357082 A CN102357082 A CN 102357082A
- Authority
- CN
- China
- Prior art keywords
- esomeprazole sodium
- agent
- sodium
- esomeprazole
- regulator
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960000496 esomeprazole sodium Drugs 0.000 title claims abstract description 44
- 238000002360 preparation method Methods 0.000 title claims abstract description 34
- 239000000843 powder Substances 0.000 title claims abstract description 17
- 238000002347 injection Methods 0.000 title claims abstract description 10
- 239000007924 injection Substances 0.000 title claims abstract description 10
- RYXPMWYHEBGTRV-JIDHJSLPSA-N sodium;5-methoxy-2-[(s)-(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]benzimidazol-3-ide Chemical compound [Na+].C([S@](=O)C=1[N-]C2=CC=C(C=C2N=1)OC)C1=NC=C(C)C(OC)=C1C RYXPMWYHEBGTRV-JIDHJSLPSA-N 0.000 title claims abstract 15
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 28
- 229910021645 metal ion Inorganic materials 0.000 claims abstract description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 48
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 24
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 23
- 229930195725 Mannitol Natural products 0.000 claims description 23
- 239000000594 mannitol Substances 0.000 claims description 23
- 235000010355 mannitol Nutrition 0.000 claims description 23
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 22
- 239000000243 solution Substances 0.000 claims description 20
- SHWNNYZBHZIQQV-UHFFFAOYSA-J EDTA monocalcium diisodium salt Chemical group [Na+].[Na+].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O SHWNNYZBHZIQQV-UHFFFAOYSA-J 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 16
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 239000008215 water for injection Substances 0.000 claims description 14
- 239000002738 chelating agent Substances 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 11
- 229910052757 nitrogen Inorganic materials 0.000 claims description 11
- 229910052799 carbon Inorganic materials 0.000 claims description 8
- 238000004108 freeze drying Methods 0.000 claims description 8
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 8
- 238000001179 sorption measurement Methods 0.000 claims description 8
- 238000003756 stirring Methods 0.000 claims description 8
- 238000001914 filtration Methods 0.000 claims description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 4
- 230000001105 regulatory effect Effects 0.000 claims description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 239000000811 xylitol Substances 0.000 claims description 2
- 235000010447 xylitol Nutrition 0.000 claims description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 2
- 229960002675 xylitol Drugs 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 6
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 239000013522 chelant Substances 0.000 abstract 1
- SUBDBMMJDZJVOS-DEOSSOPVSA-N esomeprazole Chemical compound C([S@](=O)C1=NC2=CC=C(C=C2N1)OC)C1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-DEOSSOPVSA-N 0.000 description 37
- 238000005516 engineering process Methods 0.000 description 9
- 229960004770 esomeprazole Drugs 0.000 description 7
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 229960000381 omeprazole Drugs 0.000 description 6
- 238000001291 vacuum drying Methods 0.000 description 6
- 239000003814 drug Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 4
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 4
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- 239000001116 FEMA 4028 Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 2
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 2
- 229960004853 betadex Drugs 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 235000010265 sodium sulphite Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- KWORUUGOSLYAGD-YPPDDXJESA-N esomeprazole magnesium Chemical compound [Mg+2].C([S@](=O)C=1[N-]C2=CC=C(C=C2N=1)OC)C1=NC=C(C)C(OC)=C1C.C([S@](=O)C=1[N-]C2=CC=C(C=C2N=1)OC)C1=NC=C(C)C(OC)=C1C KWORUUGOSLYAGD-YPPDDXJESA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229940112641 nexium Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940126409 proton pump inhibitor Drugs 0.000 description 1
- 239000000612 proton pump inhibitor Substances 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
实施例1 | 实施例2 | 实施例3 | |
外观形状 | 膨松 | 致密 | 致密 |
适度振摇后 | 破碎 | 未破碎 | 未破碎 |
复溶后0h澄清度和颜色 | 澄清无色 | 澄清无色 | 澄清无色 |
复溶后1h澄清度和颜色 | 澄清无色 | 澄清无色 | 淡黄色溶液 |
实施例6 | 实施例7 | 实施例8 | |
性状 | 白色块状物 | 白色块状物 | 白色块状物 |
含量 | 100.1 | 99.9 | 99.5 |
有关物质 | 0.22 | 0.29 | 0.49 |
可见异物 | 符合规定 | 符合规定 | 有2个白色小颗粒 |
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201110337537 CN102357082B (zh) | 2011-11-01 | 2011-11-01 | 一种埃索美拉唑钠的冻干粉针剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201110337537 CN102357082B (zh) | 2011-11-01 | 2011-11-01 | 一种埃索美拉唑钠的冻干粉针剂及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102357082A true CN102357082A (zh) | 2012-02-22 |
CN102357082B CN102357082B (zh) | 2013-06-05 |
Family
ID=45582501
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 201110337537 Expired - Fee Related CN102357082B (zh) | 2011-11-01 | 2011-11-01 | 一种埃索美拉唑钠的冻干粉针剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102357082B (zh) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102657622A (zh) * | 2012-05-17 | 2012-09-12 | 康普药业股份有限公司 | 一种含有埃索美拉唑钠的冻干粉针剂的制备工艺 |
CN102688205A (zh) * | 2012-06-15 | 2012-09-26 | 孙威 | 一种注射用埃索美拉唑钠制备方法 |
CN103006585A (zh) * | 2012-12-26 | 2013-04-03 | 哈药集团技术中心 | 一种注射用埃索美拉唑钠的制备 |
CN103222962A (zh) * | 2013-05-10 | 2013-07-31 | 苏州特瑞药业有限公司 | 一种注射用埃索美拉唑组合物及其制备方法 |
CN103239448A (zh) * | 2013-05-20 | 2013-08-14 | 青岛正大海尔制药有限公司 | 一种注射用埃索美拉唑钠冻干粉组合物及其制备方法 |
CN103565747A (zh) * | 2012-08-06 | 2014-02-12 | 江苏奥赛康药业股份有限公司 | 一种埃索美拉唑药物组合物及其制备方法 |
CN105001202A (zh) * | 2015-08-09 | 2015-10-28 | 朗天药业(湖北)有限公司 | 一种埃索美拉唑钠化合物及其药物组合物 |
CN105055339A (zh) * | 2015-07-31 | 2015-11-18 | 苏州汇和药业有限公司 | 注射用埃索美拉唑组合物及其制备方法 |
CN108553413A (zh) * | 2018-05-25 | 2018-09-21 | 福安药业集团湖北人民制药有限公司 | 注射用艾司奥美拉唑钠 |
CN109456306A (zh) * | 2018-10-26 | 2019-03-12 | 山西普德药业有限公司 | 一种艾司奥美拉唑钠及其包含其的冻干制剂 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100998593A (zh) * | 2006-01-12 | 2007-07-18 | 黄玉明 | 一种稳定的注射用奥美拉唑钠制剂 |
CN101513387A (zh) * | 2008-11-20 | 2009-08-26 | 李铁军 | 埃索美拉唑镁注射液 |
CN101756914A (zh) * | 2010-02-09 | 2010-06-30 | 山东新时代药业有限公司 | 一种奥美拉唑钠的冻干粉针剂及其制备方法 |
-
2011
- 2011-11-01 CN CN 201110337537 patent/CN102357082B/zh not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100998593A (zh) * | 2006-01-12 | 2007-07-18 | 黄玉明 | 一种稳定的注射用奥美拉唑钠制剂 |
CN101513387A (zh) * | 2008-11-20 | 2009-08-26 | 李铁军 | 埃索美拉唑镁注射液 |
CN101756914A (zh) * | 2010-02-09 | 2010-06-30 | 山东新时代药业有限公司 | 一种奥美拉唑钠的冻干粉针剂及其制备方法 |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102657622A (zh) * | 2012-05-17 | 2012-09-12 | 康普药业股份有限公司 | 一种含有埃索美拉唑钠的冻干粉针剂的制备工艺 |
CN102688205A (zh) * | 2012-06-15 | 2012-09-26 | 孙威 | 一种注射用埃索美拉唑钠制备方法 |
CN102688205B (zh) * | 2012-06-15 | 2013-12-11 | 孙威 | 一种注射用埃索美拉唑钠制备方法 |
CN103565747A (zh) * | 2012-08-06 | 2014-02-12 | 江苏奥赛康药业股份有限公司 | 一种埃索美拉唑药物组合物及其制备方法 |
CN103565747B (zh) * | 2012-08-06 | 2015-07-08 | 江苏奥赛康药业股份有限公司 | 一种埃索美拉唑药物组合物及其制备方法 |
CN103006585A (zh) * | 2012-12-26 | 2013-04-03 | 哈药集团技术中心 | 一种注射用埃索美拉唑钠的制备 |
CN103222962A (zh) * | 2013-05-10 | 2013-07-31 | 苏州特瑞药业有限公司 | 一种注射用埃索美拉唑组合物及其制备方法 |
CN103239448A (zh) * | 2013-05-20 | 2013-08-14 | 青岛正大海尔制药有限公司 | 一种注射用埃索美拉唑钠冻干粉组合物及其制备方法 |
CN105055339A (zh) * | 2015-07-31 | 2015-11-18 | 苏州汇和药业有限公司 | 注射用埃索美拉唑组合物及其制备方法 |
CN105001202A (zh) * | 2015-08-09 | 2015-10-28 | 朗天药业(湖北)有限公司 | 一种埃索美拉唑钠化合物及其药物组合物 |
CN108553413A (zh) * | 2018-05-25 | 2018-09-21 | 福安药业集团湖北人民制药有限公司 | 注射用艾司奥美拉唑钠 |
CN108553413B (zh) * | 2018-05-25 | 2020-07-07 | 福安药业集团湖北人民制药有限公司 | 注射用艾司奥美拉唑钠 |
CN109456306A (zh) * | 2018-10-26 | 2019-03-12 | 山西普德药业有限公司 | 一种艾司奥美拉唑钠及其包含其的冻干制剂 |
Also Published As
Publication number | Publication date |
---|---|
CN102357082B (zh) | 2013-06-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102357082B (zh) | 一种埃索美拉唑钠的冻干粉针剂及其制备方法 | |
US11801239B2 (en) | Powder injection of the donepezil semi palmoxiric acid salt, composition containing same and preparation method therefor | |
CN101244043A (zh) | 比伐卢定冻干粉针剂及其制备方法 | |
CN101167730B (zh) | 一种复方倍他米松混悬型注射液 | |
CN101703483B (zh) | 一种奥美拉唑钠冻干粉针剂及其制备方法 | |
CN102525963B (zh) | 一种硫酸奈替米星冻干粉针及其制备方法 | |
KR20090095668A (ko) | 포르시토사이드 주사제와 그 제조 방법 | |
CN105726472A (zh) | 苯达莫司汀药剂组合物及应用 | |
RU2519654C2 (ru) | Лиофилизированный препарат на основе тетродотоксина и способ его производства | |
CN103860483A (zh) | 复方甘草酸苷类冻干粉针注射剂及其制备方法 | |
CN102512379B (zh) | 一种新型棘白菌素类抗真菌药物组合物及其制备方法 | |
CN104971049A (zh) | 一种含有福沙匹坦的冻干制剂及其制备方法 | |
CN104800172B (zh) | 注射用卡络磺钠粉针剂和制法 | |
CN103845295A (zh) | 一种注射用帕洛诺司琼制剂及其制备方法 | |
EP3984524A1 (en) | Ornidazole injection and s-ornidazole injection | |
CN102210686A (zh) | 一种含更昔洛韦化合物的药物组合物及其制备方法 | |
CN102488663A (zh) | 一种二乙酰氨乙酸乙二胺药物组合物及其制备方法 | |
CN102670524B (zh) | 一种注射用泮托拉唑钠冻干制剂及其制备方法 | |
CN103768011A (zh) | 福多司坦注射剂及其制备方法 | |
CN103142509A (zh) | 一种注射用硼替佐米药物组合物 | |
CN103565747B (zh) | 一种埃索美拉唑药物组合物及其制备方法 | |
CN102441160B (zh) | 一种胸腺肽α1药物组合物及其制备方法 | |
CN102274194B (zh) | 一种含托烷司琼化合物的药物组合物及其制备方法 | |
CN103462888B (zh) | 一种取代的β-环糊精包合的长春西汀注射液及其制备方法 | |
CN103330682B (zh) | 穿琥宁注射液和制法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C53 | Correction of patent of invention or patent application | ||
CB02 | Change of applicant information |
Address after: 210046 Nanjing economic and Technological Development Zone, Jiangsu Heng Road, No. 28 Applicant after: NANJING YOKO PHARMACEUTICAL Co.,Ltd. Applicant after: NANJING YOKO BIOMEDICAL R & D Ltd. Address before: 210046 Nanjing economic and Technological Development Zone, Jiangsu Heng Road, No. 28 Applicant before: NANJING XINGANG MEDICAL Co.,Ltd. Applicant before: NANJING YOKO BIOMEDICAL R & D Ltd. Applicant before: NANJING YOKO PHARMACEUTICAL Co.,Ltd. |
|
COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: NANJING XINGANG PHARMACEUTICAL CO., LTD. TO: NANJING YOKO PHARMACEUTICAL CO., LTD. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee | ||
CP01 | Change in the name or title of a patent holder |
Address after: 210046 Nanjing economic and Technological Development Zone, Jiangsu Heng Road, No. 28 Patentee after: NANJING YOKO PHARMACEUTICAL Co.,Ltd. Patentee after: NANJING YOKO BIOMEDICAL R & D Ltd. Patentee after: NANJING YOKO BIOLOGICAL PHARMACEUTICAL GROUP Co.,Ltd. Address before: 210046 Nanjing economic and Technological Development Zone, Jiangsu Heng Road, No. 28 Patentee before: NANJING YOKO PHARMACEUTICAL Co.,Ltd. Patentee before: NANJING YOKO BIOMEDICAL R & D Ltd. Patentee before: Nanjing uniclever biological pharmaceutical Limited by Share Ltd. Address after: 210046 Nanjing economic and Technological Development Zone, Jiangsu Heng Road, No. 28 Patentee after: NANJING YOKO PHARMACEUTICAL Co.,Ltd. Patentee after: NANJING YOKO BIOMEDICAL R & D Ltd. Patentee after: Nanjing uniclever biological pharmaceutical Limited by Share Ltd. Address before: 210046 Nanjing economic and Technological Development Zone, Jiangsu Heng Road, No. 28 Patentee before: NANJING YOKO PHARMACEUTICAL Co.,Ltd. Patentee before: NANJING YOKO BIOMEDICAL R & D Ltd. |
|
CP03 | Change of name, title or address |
Address after: 210046 Nanjing economic and Technological Development Zone, Jiangsu Heng Road, No. 28 Patentee after: NANJING YOKO PHARMACEUTICAL Co.,Ltd. Patentee after: NANJING YOKO BIOMEDICAL R & D Ltd. Address before: 210046 Nanjing economic and Technological Development Zone, Jiangsu Heng Road, No. 28 Patentee before: NANJING YOKO PHARMACEUTICAL Co.,Ltd. Patentee before: NANJING YOKO BIOMEDICAL R & D Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130605 |